The Biologics News and Reports Portal

Show Cart

Target Pipelines

Results 41 - 50 of 66

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

450.00 €

Aug 2017 Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

300.00 €

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

150.00 €

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

400.00 €

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

200.00 €

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

1,140.00 €

1,900.00 €

(Discount: 40.00%)

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

700.00 €

Oct 2016 Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016

200.00 €

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

500.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

250.00 €

Shopping cart

Cart empty

Shopping cart

Cart empty

Latest report

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Target Pipelines

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

Aug 2017 Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Oct 2016 Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing